Table 2 Baseline characteristics
Use following csDMARD-IR | Use following first bDMARD-IR | |||||
|---|---|---|---|---|---|---|
Abatacept | TNFi | p value | Abatacept | TNFi | p value | |
n | 92 | 613 | – | 105 | 212 | – |
Age, years | 49.3 (13.6) | 47.3 (13.2) | 0.1871 | 45.9 (14.4) | 45.5 (13.0) | 0.8197 |
Disease duration, years | 7.0 (7.8) | 6.8 (7.7) | 0.7980 | 12.1 (10.4) | 10.0 (8.8) | 0.0660 |
Female, n (%) | 71 (77.2) | 476 (77.7) | 0.8940 | 84 (80.0) | 156 (73.6) | 0.2655 |
Concomitant medication use, n (%) | ||||||
csDMARDs | 87 (94.6) | 567 (92.5) | 1.0000 | 87 (82.9) | 174 (82.1) | 1.0000 |
MTX | 69 (75.0) | 466 (76.0) | 0.7955 | 69 (65.7) | 142 (67.0) | 0.8994 |
HCQ | 72 (78.3) | 350 (57.1) | < 0.0001 | 43 (41.0) | 72 (34.0) | 0.2640 |
SSZ | 11 (12.0) | 45 (7.3) | 0.1455 | 9 (8.6) | 10 (4.7) | 0.2095 |
LEF | 7 (7.6) | 54 (8.8) | 0.8434 | 7 (6.7) | 16 (7.5) | 1.0000 |
Corticosteroids | 45 (48.9) | 282 (46.0) | 0.6542 | 73 (69.5) | 93 (43.9) | < 0.0001 |
Number of oral corticosteroid prescriptions per 100 person-years of treatment | 81.24 | 44.02 | 99.03 | 76.23 | ||
TNFi used, n (%) | N/A | N/A | ||||
Adalimumab | 146 (23.8) | 58 (27.4) | ||||
Certolizumab | 62 (10.1) | 27 (12.7) | ||||
Etanercept | 239 (39.0) | 69 (32.5) | ||||
Golimumab | 105 (17.1) | 29 (13.7) | ||||
Infliximab (Remicade) | 60 (9.8) | 26 (12.3) | ||||
Infliximab (Inflectra) | 1 (0.2) | 3 (1.4) | ||||
Comorbidities | ||||||
Age-adjusted CCI | 2.8 (1.4) | 2.4 (1.3) | 0.2403 | 2.9 (1.8) | 2.6 (1.5) | 0.2228 |
Hyperlipidemia, n (%) | 28 (30.4) | 193 (31.5) | 0.9044 | 42 (40.0) | 75 (35.4) | 0.4589 |
Hyperglycemia, n (%) | 13 (14.1) | 82 (13.4) | 0.8699 | 11 (10.5) | 32 (15.1) | 0.2987 |
Hypertension, n (%) | 37 (40.2) | 290 (47.3) | 0.2187 | 58 (55.2) | 110 (51.9) | 0.6329 |
COPD, n (%) | 37 (40.2) | 194 (31.6) | 0.1211 | 43 (41.0) | 76 (35.8) | 0.3905 |
CVD, n (%) | 11 (12.0) | 75 (12.2) | 1.0000 | 19 (18.1) | 37 (17.5) | 0.8769 |
Charlson Comorbidity Index | 1.4 (0.9) | 1.2 (0.7) | 0.0039 | 1.4 (1.2) | 1.3 (0.8) | 0.59 |
RF+, n (%) | 69 (75.0) | 424 (69.2) | 0.2680 | 73 (69.5) | 141 (66.5) | 0.7020 |
ACPA+, n (%) | 56 (60.9) | 358 (58.4) | 1.0000 | 55 (52.4) | 107 (50.5) | 1.0000 |
ESR, mm/h | 18.7 (16.0) | 24.5 (19.8) | 0.0080 | 21.9 (19.2) | 24.8 (20.8) | 0.3164 |
CRP, mg/L | 14.30 (20.20) | 12.90 (20.40) | 0.5875 | 16.30 (23.40) | 11.80 (19.40) | 0.1226 |
Patient-reported outcomes | ||||||
Patient global, VAS 0–10 | 5.6 (2.4) | 4.8 (2.8) | 0.0430 | 5.2 (2.7) | 4.4 (2.9) | 0.0324 |
Patient pain, VAS 0–10 | 6.1 (2.6) | 5.3 (3.0) | 0.0401 | 5.7 (3.0) | 5.0 (3.1) | 0.1157 |
Patient fatigue, VAS 0–10 | 5.8 (2.8) | 4.7 (3.2) | 0.0099 | 5.7 (2.8) | 4.8 (3.3) | 0.0597 |
Morning stiffness, min | 155.0 (308.3) | 120.9 (274.1) | 0.3676 | 127.3 (294.7) | 93.0 (244.5) | 0.3597 |
HAQ | 1.31 (0.61) | 1.24 (0.60) | 0.3661 | 1.51 (0.60) | 1.18 (0.66) | 0.0006 |
Physician global, VAS 0–10 | 4.8 (2.7) | 4.0 (2.6) | 0.0370 | 4.0 (2.6) | 3.4 (2.6) | 0.2256 |
Swollen joint count, 0–28 | 8.5 (5.2) | 7.4 (5.3) | 0.1409 | 7.7 (5.3) | 6.5 (6.0) | 0.1755 |
Tender joint count, 0–28 | 6.8 (6.4) | 6.6 (5.7) | 0.8451 | 7.3 (6.1) | 5.4 (5.9) | 0.0481 |
Disease activity measures | ||||||
CDAI | 26.3 (12.7) | 23.5 (11.7) | 0.1416 | 24.8 (11.0) | 18.8 (12.5) | 0.0069 |
SDAI | 28.6 (13.1) | 24.7 (12.0) | 0.0639 | 26.3 (11.7) | 20.4 (12.6) | 0.0140 |
DAS28-4, ESR | 4.8 (1.3) | 4.7 (1.3) | 0.7557 | 4.8 (1.2) | 4.5 (1.4) | 0.3621 |